NCT00706134

Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Elderly Patients With Essential Hypertension When Given With a Light Meal in a 8 Week Placebo-controlled Study

An Eight-week Double-blind, Multi-center, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Elderly Patients With Essential Hypertension When Given With a Light Meal

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 756 (actual)
• Sponsor: Novartis · Industry
• Sex: All
• Age: 65 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the efficacy and safety of aliskiren 75 mg, 150 mg, and 300 mg in elderly patients with essential hypertension when given with a light meal.

Conditions

• Hypertension

Interventions

Type	Name	Description
DRUG	Placebo	Placebo tablet taken once daily in the morning with a light meal.
DRUG	Aliskiren 75 mg	Aliskiren 75 mg tablet taken once daily in the morning with a light meal.
DRUG	Aliskiren 150 mg	Aliskiren 150 mg tablet taken once daily in the morning with a light meal.
DRUG	Aliskiren 300 mg	Aliskiren 300 mg tablet taken once daily in the morning with a light meal.

Timeline

• Start date: 2008-05-01
• Primary completion: 2009-04-01
• Completion: 2009-04-01
• First posted: 2008-06-27
• Last updated: 2011-06-28
• Results posted: 2011-06-17

Locations

8 sites across 8 countries: Argentina, Czechia, Germany, Iceland, Italy, Netherlands, Poland, Slovakia